NeuVax vaccine

BIOLOGICAL2 trials

Sponsors

George E. Peoples, Cancer Insight, LLC

Conditions

Breast Cancer

Phase 2

Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax

CompletedNCT01570036

George E. PeoplesBreast Cancer

Start: 2013-05-21End: 2018-09-28Updated: 2020-12-02

Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients

CompletedNCT02297698

Cancer Insight, LLCBreast Cancer

Start: 2014-10-31End: 2021-12-31Updated: 2023-12-12

Related Papers

Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer

Clinical Cancer Research2020-02-1888 citations

Immunologic responses in triple-negative breast cancer patients in a randomized phase IIb trial of nelipepimut-S plus trastuzumab versus trastuzumab alone to prevent recurrence.

Journal of Clinical Oncology2019-05-201 citations

Final analysis of nelipepimut-S plus GM-CSF with trastuzumab versus trastuzumab alone to prevent recurrences in high-risk, HER2 low-expressing breast cancer: A prospective, randomized, blinded, multicenter phase IIb trial.

Journal of Clinical Oncology2019-03-1019 citations

Pre-specified interim analysis of a randomized phase IIb trial of trastuzumab + nelipeptimut-S (NeuVax) vs trastuzumab for the prevention of recurrence demonstrates benefit in triple negative (HER2 low-expressing) breast cancer patients

Annals of Oncology2018-10-014 citations